The study will be done in 2017 to evaluate the effects of flaxseed on the blood pressure, blood cholesterol level, and body mass index of hypertensive patients who are hospitalized in the Heart Clinic of Shohadaye Ashayer hospital, Khorramabad, Iran.
114 patients will be recruited through sequential non-random sampling and will be randomly allocated to three groups through block randomization.
Eligibility criteria include: age between 35 to 70 years old, affliction by mild or moderate hypertension as diagnosed by a specialist, and no use of angiotensin converting enzyme inhibitors. Patients will be excluded if they develop diarrhea, inflammatory bowel disease, bowel obstruction, or allergy or need any kind of surgery during the course of the study.
This is a three-group randomized clinical trial. Patients will be allocated to a 10-gram flaxseed, a 30-gram flaxseed, and a placebo (wheat flour) group. Blood pressure (primary outcome), body mass index, and blood cholesterol level (secondary outcomes) will be measured before, six and twelve weeks after the intervention. Razi Research Center will prepare three pack series of 10-gram flaxseed, 30-gram flaxseed, and wheat flour and will label them A, B, C, respectively. Patients will be asked to use the allocated pack after lunch for twelve weeks. At the end of each week, we will make telephone contacts with patients in order to assess their adherence to the treatments as well as the incidence of adverse effects of the treatments.